海洋生物源抗高血压肽的制备和构效关系研究进展

Recent Development on Production and QSAR of Marine-derived Antihypertensive Peptides

高血压已成为全球最常见的心血管疾病,其中肾素-血管紧张素-醛固酮系统(renin-angiotensin-aldosterone system,RAAS)发挥着重要的血压调节作用,血管紧张素转化酶(angiotensin-converting enzyme,ACE)催化血管紧张素Ⅰ转化为血管紧张素Ⅱ,并使缓激肽失活,因此,其抑制剂成为抗高血压药物研究的靶点。许多研究表明小肽具有ACE活性抑制作用,存在调控高血压的潜力。海洋生物种类丰富,具有潜在的生物活性肽的开发价值。对来自海洋生物的抗高血压生物活性肽的生产和构效关系(Structure-Activity Relationship,SAR)的研究现状进行综述。

Hypertension has become one of the most common cardiovascular disease,in which renin-angiotensin aldosterone system（ RAAS）plays an important role in regulating blood pressure. Thus,angiotensin converting enzyme（ Angiotensin-Converting Enzyme,ACE） inhibitors becomes the target of antihypertensive drugs. At present,many studies showed that some protein-derived peptides have ACE inhibition activity,which is the potential for regulating high blood pressure. Marine organism is rich in species and has the potential of developing bioactive peptides. In this paper,the preparation and the structure-activity relationship（ SAR） of the antihypertensive bioactive peptides from Marine organisms were reviewed.